FDA Clears Breakthrough Pancreatic Cancer Drug That Nearly Doubles Survival
What Happened
The US FDA has approved daraxonrasib (Rasonque), a first-of-its-kind pancreatic cancer drug for adults with advanced disease. In clinical trials, patients taking the drug lived a median 13.2 months, compared with 6.7 months for those receiving standard chemotherapy.
Key Takeaways
The once-daily pill targets RAS mutations that drive most pancreatic cancers, marking a major treatment advance for one of the deadliest forms of cancer.